Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018 . . .
This content is restricted to subscribers
Newsmakers
CytoDyn (OTC: CYDY) to Deliver Presentation at Biotech Showcase Conference
BLA update and major licensing initiatives in cancer and immunology VANCOUVER, Washington, Jan 08, 2019- CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that […]
Healthcare
CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019
VANCOUVER, Washington, Feb. 27, 2019 — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab […]
Healthcare
CytoDyn’s (OTC: CYDY) Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks
Based on strong results in its pre-clinical animal study, CytoDyn files for Orphan Drug Designation for Triple-Negative Breast Cancer VANCOUVER, Washington, Feb 20, 2019 – CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized […]